Additional file 3 of Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial

Additional file 3: Figure S1. (a) Treatment response for each patient in different treatment cycles (b) A significant correlation was identified between radiological response and pathological response. (c) The difference in OS between the adjuvant immunotherapy maintenance group and the non-maintena...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Zhu, Xinsheng, Sun, Liangdong, Song, Nan, He, Wenxin, Xie, Boxiong, Hu, Junjie, Zhang, Jing, Yang, Jie, Dai, Jie, Bian, Dongliang, Xia, Haoran, Sun, Fenghuan, Xiong, Anwen, Luo, Jie, Zhang, Lele, Yu, Huansha, Liu, Ming, Liu, Hongcheng, Wang, Haifeng, Zhang, Haiping, Chen, Chang, Wu, Chunyan, Duan, Liang, Zhu, Yuming, Zhang, Peng, Jiang, Gening
Format:	Bild
Sprache:	eng
Schlagworte:	Cancer FOS: Biological sciences FOS: Clinical medicine Genetics Immunology Marine Biology Medicine Molecular Biology Pharmacology Physiology Science Policy
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Additional file 3: Figure S1. (a) Treatment response for each patient in different treatment cycles (b) A significant correlation was identified between radiological response and pathological response. (c) The difference in OS between the adjuvant immunotherapy maintenance group and the non-maintenance group. (d) The difference in PFS between the adjuvant immunotherapy maintenance group and the non-maintenance group. (e) The difference in OS between the PD-L1 positive group and the negative group. (f) The difference in PFS between the PD-L1 positive group and the negative group.
DOI:	10.6084/m9.figshare.22601354